Janssen puzzled by Denmark's refusal of antidepressant nasal spray

The Danish Medicines Council has once again refused to approve Janssen’s nasal spray for treatment-resistant depression, dubbed Spravato. The decision surprises Julie Brooker, Janssen’s country director for Denmark, as other European countries have given conditional approvals.

Reaffirming earlier decisions, the Danish Medicines Council has deemed Janssen's nasal spray against depression unfit for Danish patients | Photo: Sisse Dupont/INDBLIK

Janssen’s antidepressant nasal spray is not welcome in Denmark.

The Danish Medicines Council has once again turned up its nose at Spravato (esketamine) as a relevant treatment choice for treatment-resistant depression in combination with SNRIs (serotonin and norepinephrine reuptake inhibitors) or SSRIs (selective serotonin reuptake inhibitors).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs